會(huì)員.png)
QQ交談
MSN交談
您所在位置：請(qǐng)輸入產(chǎn)品關(guān)鍵字：
郵編：510660
聯(lián)系人：楊永漢
電話(huà)：86-020-82574011
傳真：86-020-32206070
手機(jī)：13802525278
留言：發(fā)送留言
個(gè)性化：www.jianlun45.com
網(wǎng)址：www.jianlun.com
商鋪：http://www.muquzhou.cn/st199246/
akari立克次體 IgG ELISA試劑盒
- 發(fā)布日期：
- 有效日期：
- 所 在 地：
- 產(chǎn) 地：
- 已獲點(diǎn)擊：
- 2024年11月5日
- 2025年5月5日
- 廣東廣州市
- 美國(guó)
- 133次
【產(chǎn)品簡(jiǎn)介】
【詳細(xì)說(shuō)明】
akari立克次體 IgG ELISA試劑盒
R. akari IgG ELISA Kit
廣州健侖生物科技有限公司
主要用途：用于檢測(cè)人血清中的akari立克次體IgG抗體
產(chǎn)品規(guī)格：96T/盒
主要產(chǎn)品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲(chóng)病、立克次體、果氏巴貝西蟲(chóng)、馬焦蟲(chóng)、牛焦蟲(chóng)、利什曼蟲(chóng)、新包蟲(chóng)、弓形蟲(chóng)、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。
akari立克次體 IgG ELISA試劑盒
我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無(wú)形體、蜱蟲(chóng)、恙蟲(chóng)、利什曼原蟲(chóng)、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
歡迎咨詢(xún)
歡迎咨詢(xún)2042552662
| JL-FL38 | parkeri立克次體IgG ELISA | R. parkeri IgG ELISA Kit |
| JL-FL39 | montanensis立克次體IgG ELISA | R. montanensis IgG ELISA Kit |
| JL-FL40 | EB病毒衣殼IgG免疫熒光玻片試劑盒 | EBV Viral Capsid IgG IFA Kit |
| JL-FL41 | EB病毒衣殼IgM免疫熒光玻片試劑盒 | EBV Viral Capsid IgM IFA Kit |
| JL-FL42 | EB病毒早期抗原IgG免疫熒光玻片試劑盒 | EBV Early Antigens IgG IFA Kit |
| JL-FL43 | 鉤端螺旋體IgG免疫熒光試劑盒 | Leptospira IgG IFA Kit |
| JL-FL44 | 鉤端螺旋體IgM免疫熒光試劑盒 | Leptospira IgM IFA Kit |
| JL-FL45 | 果氏巴貝西蟲(chóng)免疫熒光玻片 | Babesia microti IFA Substrate slide |
| JL-FL46 | 果氏巴貝西蟲(chóng)IgG免疫熒光試劑盒 | Babesia microti IgG IFA Kit |
| JL-FL47 | 果氏巴貝西蟲(chóng)IgM免疫熒光試劑盒 | Babesia microti IgM IFA Kit |
| JL-FL48 | 埃立克體IgG微量免疫熒光試劑盒 | Ehrlichia canis Canine IFA IgG Kit |
| JL-FL49 | 包柔氏螺旋體菌IgG免疫熒光試劑盒 | Borrelia IgG IFA Kit |
| JL-FL50 | 布魯氏菌IgG免疫熒光試劑盒 | Brucella IgG IFA Kit |
| JL-FL51 | 里氏新立克次體IgG免疫熒光試劑盒 | Neorickettsia risticii IgG IFA Kit |
| JL-FL52 | 弓形蟲(chóng)IgG免疫熒光試劑盒（檢測(cè)貓） | Toxoplasma IFA Feline IgG Kit |
| JL-FL53 | 弓形蟲(chóng)IgG免疫熒光試劑盒（檢測(cè)狗） | Toxoplasma IFA Canine IgG Kit |
二維碼掃一掃
【公司名稱(chēng)】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】
利用酵母和人類(lèi)細(xì)胞，Smerdon，Mao和他們的研究團(tuán)隊(duì)發(fā)現(xiàn)，正常的TCR修復(fù)過(guò)程有兩個(gè)關(guān)鍵的步驟，以及一種叫做H2B的染色質(zhì)蛋白質(zhì)在*步中起著至關(guān)重要的作用。
為了幫助修復(fù)酶能夠進(jìn)入被大力保護(hù)的DNA中，H2B首先會(huì)解開(kāi)一個(gè)較小的蛋白質(zhì)的扣子，就像你在一頓豐富的大餐后放松你的皮帶一樣，這使得DNA鏈放松和分開(kāi)。隨著鏈的打開(kāi)，維修人員才有空間進(jìn)來(lái)和清楚損傷區(qū)域。
這較小的蛋白質(zhì)的解開(kāi)，被稱(chēng)為deubiquitylation。Smerdon和Mao說(shuō)，這個(gè)過(guò)程使得DNA的修復(fù)效率更高，并且沒(méi)有它的修復(fù)是不可能的。
他們的發(fā)現(xiàn)作為進(jìn)一步研究染色質(zhì)中的DNA修復(fù)在很大程度上的未知領(lǐng)域的基礎(chǔ)。他們的目標(biāo)是更好地了解這一過(guò)程在人類(lèi)身上的工作機(jī)理。
基因療法
“即使在基本技術(shù)層面上，我也沒(méi)有忽視這項(xiàng)研究zui終對(duì)人體健康而言所能做的，” Smerdon說(shuō)。
“其中一個(gè)正在開(kāi)發(fā)的治療方法是靶向基因療法，”他說(shuō)。“如果一個(gè)病人有一個(gè)特定的基因突變，這個(gè)療法會(huì)為他們提供一個(gè)正常的拷貝來(lái)試圖糾正變異基因。雖然它已在某些疾病已經(jīng)成功地做到這一點(diǎn)，但它仍然被修復(fù)缺陷案例中研究。”
Mao推測(cè)，在未來(lái)，有DNA修復(fù)問(wèn)題的人可能會(huì)吃一種可以提供修復(fù)酶活性的藥物，就可以達(dá)到治療的目的。但這個(gè)想法還沒(méi)有任何臨床試驗(yàn)。
周?chē)窠?jīng)損傷后的自身功能恢復(fù)往往有限，因此，生物工程神經(jīng)移植物復(fù)合細(xì)胞外基質(zhì)分子，生長(zhǎng)因子,藥物學(xué)輔助，及細(xì)胞移植修復(fù)周?chē)窠?jīng)損傷等都成為研究熱點(diǎn)。脂肪干細(xì)胞已被證實(shí)具有成脂肪，成骨，成軟骨 多種分化潛能，因其材料來(lái)源廣泛，取材容易，分化為神經(jīng)元能力強(qiáng)，倫理學(xué)爭(zhēng)議少等優(yōu)點(diǎn)，使其成為神經(jīng)導(dǎo)管上覆蓋的優(yōu)秀種子細(xì)胞。
英國(guó)曼徹斯特大學(xué)炎癥與修復(fù)研究所Blond McIndoe 實(shí)驗(yàn)室主要研究GABA及其他神經(jīng)遞質(zhì)周?chē)窠?jīng)系統(tǒng)及成體干細(xì)胞中的作用，他們發(fā)現(xiàn)，特異性抑制P2X7受體能夠拯救ATP誘發(fā)細(xì)胞死亡，這可能解決神經(jīng)損傷處干細(xì)胞移植成活率低的問(wèn)題。作者的研究可能為神經(jīng)修復(fù)結(jié)合細(xì)胞療法和藥物干預(yù)的發(fā)展指出新的方向。相關(guān)研究觀點(diǎn)發(fā)表在《中國(guó)神經(jīng)再生研究(英文版)》雜志2014年7月第14 期雜志上。
Using yeast and human cells, Smerdon, Mao and their team found two key steps in the normal TCR repair process, as well as a chromatin protein called H2B that plays a crucial role in the first step.
To help the repair enzyme get into well-protected DNA, H2B will first unbutton a smaller protein just as you relax your belt after a rich meal, which relaxes and separates the DNA strand . As the chain opens, maintenance personnel have room to come in and clear the damaged area.
The solution of this smaller protein is called deubiquitylation. Smerdon and Mao said that this process makes the DNA repair more efficient, and without its repair is impossible.
Their findings serve as a basis for furthering the largely unknown area of ??DNA repair in chromatin. Their goal is to better understand the working mechanism of this process on human beings.
Gene therapy
"Even at the basic technical level, I did not neglect what the research could ultimay do to human health," Smerdon said.
"One of the treatments that is being developed is targeted gene therapy," he said. "If a patient has a particular mutation, the therapy will provide them with a normal copy in an attempt to correct the variant gene.Although it has been successfully done in certain diseases, it is still being fixed in the case of defects the study."
Mao speculated that in the future, people with DNA repair problems may eat a drug that provides repair enzyme activity for therapeutic purposes. But this idea has not had any clinical trial yet.
Peripheral nerve injury after their own functional recovery is often limited, therefore, bioengineered nerve graft compound extracellular matrix molecules, growth factors, pharmacological assistance, and cell transplantation to repair peripheral nerve injury have become the research hotspot. Adipose-derived stem cells have been proven to have multiple adipogenic, osteogenic, and cartilage potential for differentiation because of their wide range of materials, ease of harvesting, strong ability to differentiate into neurons, and less ethical controversy that make them neurotransduction-covered Excellent seed cells.
The Blond McIndoe Laboratory at the Institute of Inflammation and Rehabilitation, University of Manchester, UK, has been investigating the role of GABA and other neurotransmitter peripheral and adult stem cells. They found that specifically inhibiting P2X7 receptors can rescue ATP-induced cell death, which may account for nerve Damage stem cell transplantation survival rate is low. The authors study may point out a new direction for the development of neurorestoratin combined with cell therapy and drug intervention. Relevant research point of view published in the "Chinese Journal of Nerve Regeneration Research (English version)" magazine in July 2014 No. 14 magazine.